SPY412.86+1.22 0.30%
DIA336.79-0.76 -0.23%
IXIC13,996.10+146.10 1.05%

Amathus Therapeutics, Merck In Agreement For Neurodegenerative Disease-Targeted Therapies

Privately-held Amathus Therapeutics has entered into a strategic collaboration wi

· 03/17/2021 09:52

Privately-held Amathus Therapeutics has entered into a strategic collaboration with Merck & Co (NYSE: MRK) to develop novel small molecule therapeutic candidates for neurodegenerative diseases.

  • Under the terms of the agreement, Amathus will be responsible for identifying and progressing novel chaperone activators through preclinical discovery.
  • Merck has the option to acquire Amathus Therapeutics and its pipeline of mitochondrial-targeted candidates for the treatment of neurodegenerative disorders and renal diseases.
  • Amathus will receive an upfront payment from Merck. If Merck exercises its option, Amathus will be eligible for milestone payments associated with candidates' successful development above $500 million per program.
  • Price Action: MRK shares are down 0.35% at $76.54 on the last check Wednesday.